

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6852965

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RICHARD PRESTON MASON	07/27/2021
RECEIVING PARTY DATA	
Name:	AMARIN PHARMACEUTICALS IRELAND LIMITED
Street Address:	2 PEMBROKE HOUSE
Internal Address:	UPPER PEMBROKE STREET 28-32
City:	DUBLIN
State/Country:	IRELAND
Postal Code:	2
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	62012739
Application Number:	62051032
Application Number:	62127117
Application Number:	62171637
Application Number:	15312113
Application Number:	16188905
CORRESPONDENCE DATA	
Fax Number:	(206)359-7198
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2063598000
Email:	dkusek@perkinscoie.com, patentprocurement@perkinscoie.com
Correspondent Name:	PERKINS COIE LLP
Address Line 1:	PO BOX 1247
Address Line 4:	SEATTLE, WASHINGTON 98111-1247
ATTORNEY DOCKET NUMBER:	88896-8071.US05 THRU US00
NAME OF SUBMITTER:	DEBBIE KUSEK
SIGNATURE:	/debbie kusek/
DATE SIGNED:	08/06/2021

Total Attachments: 3

source=8071.US family Mason signed assignment#page1.tif

source=8071.US family Mason signed assignment#page2.tif

source=8071.US family Mason signed assignment#page3.tif

ASSIGNMENT

WHEREAS, the undersigned, to wit: Richard Preston Mason (hereinafter "ASSIGNOR"), is the lawful owner of the inventions listed in "Schedule 1" attached hereto;

AND WHEREAS, Amarin Pharmaceuticals Ireland Limited (hereinafter "ASSIGNEE"), a corporation duly organized and existing under the laws of Ireland and having its principal office and place of business 2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2, Ireland, desires to acquire the entire right, title, and interest therein of all inventions listed in "Schedule 1";

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, said ASSIGNOR does hereby sell, assign, and transfer, and hereby set over unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to said inventions in the United States of America and all foreign countries, including, without limitation, said inventions as described in the applications listed in "Schedule 1," to be held and enjoyed by said ASSIGNEE, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR had this assignment and sale not been made, including, without limitation, all rights to the aforesaid applications and to any United States Letters Patent therefor, when issued together with all improvements thereon and betterments thereof, all related applications including, but not limited to, divisions, continuations, continuations-in-part, reissues and reexaminations thereof and substitutions of or for said applications, and all foreign rights including the right to make applications for Letters Patent for said inventions in any and all foreign countries and the right to claim priority as to the filing date under the International Convention on the basis for the aforesaid applications for United States Letters Patent; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents to issue all Letters Patent issuing therefrom to ASSIGNEE, for its interest as ASSIGNEE, its successors, assigns and legal representatives.

ASSIGNOR hereby agrees to execute any papers, provide any information and testify in any interference or litigation at the request of ASSIGNEE, its successors, assigns and legal representatives, when deemed essential to ASSIGNEE's, its successors', assigns' and legal representatives' full enjoyment, protection, enforcement and title in and to such inventions and rights hereby transferred.

ASSIGNOR furthermore agrees upon request of said ASSIGNEE, its successors, assigns and legal representatives, and without further remuneration, to execute any and all papers desired by said ASSIGNEE, its successors, assigns and legal representatives, for the filing and granting of foreign applications and the perfecting of title thereto in said ASSIGNEE, its successors, assigns and legal representatives.

Signature



Date Signed

July 27, 2021

Name: Richard Preston Mason


Address: 100 Cummings Center
Suite 135L
181 Elliott St
Beverly, MA 01915

ACKNOWLEDGED AND AGREED:

On behalf of: Amarin Pharmaceuticals Ireland Limited

Date: July 28, 2021

Signature:



Signature

Michael W. Kalb

Printed Name

CFO, SVP of Amarin Pharma, Inc.

On behalf of Amarin Pharmaceuticals Ireland
Limited

Schedule I

Application No.	Country	Title	Filing Date	Atty. Docket No.
62/012,739	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL IN A HYPERTRIGLYCERIDEMIC SUBJECT	06/16/2014	88896-8071.US00
62/051,032	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL IN A HYPERTRIGLYCERIDEMIC SUBJECT	09/16/2014	88896-8071.US01
62/127,117	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL IN A HYPERTRIGLYCERIDEMIC SUBJECT	03/02/2015	88896-8071.US02
62/171,637	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL IN A HYPERTRIGLYCERIDEMIC SUBJECT	06/05/2015	88896-8071.US03
PCT/US15/36027	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL IN A HYPERTRIGLYCERIDEMIC SUBJECT	06/16/2015	88896-8071.WO00
15/312,113	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL IN A HYPERTRIGLYCERIDEMIC SUBJECT	11/17/2016	88896-8071.US04
16/188,905	US	METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL OR MEMBRANE POLYUNSATURATED FATTY ACIDS	01/13/2018	88896-8071.US05